|Articles|August 9, 2021
- Pharmaceutical Executive-08-01-2021
- Volume 41
- Issue 8
Pharmaceutical Executive, August 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive August 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 5 years ago
Why the Pandemic is Rewriting the Biopharma Rule Bookalmost 5 years ago
Primary Care in Crisis: PCP Navigation in a Specialty Worldalmost 5 years ago
A Brave New World: Optimizing Access in Wake of COVIDalmost 5 years ago
By Any Genes Necessary: The Role of MEAs for Gene Therapiesalmost 5 years ago
A Framework for Future: Strengthening Market Access Competenciesalmost 5 years ago
Value Risk and Reward: Taking Stock of Value-Based Contracts in Pharmaalmost 5 years ago
A Global Vision for Accessalmost 5 years ago
Early Payer-Related Lessons for Pharma Post-Aduhelm Approvalalmost 5 years ago
Biotech Capital Markets Continue to UnderperformAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA’s Advisory Panel Votes in Favor of Updating Covid-19 Vaccine Shots to Target XFG Variant
2
CVS Restores Coverage of Lilly’s Zepbound, Adds Oral Obesity Drug Foundayo
3
WHO Prioritizes Three Experimental Treatments for Bundibugyo Ebola Strain
4
FDA's Timeline for DTC Prescription Drug Ad Oversight
5